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Table 2. NYHA functional class, echocardiographic indices, and plasma BNP
levels before and after therapeutic intervention in study groups.
Pre-
treatment
Post-
treatment p a Change p b
NYHA
class
0,010
Grup I 3 (3-4) 2 (2-3) <0,001 -1 (-2 - -1)
Group II 4 (3-4) 3 (3-4) 0,083 0 (-1 - 0)
BNP
(pg/ml)
<0,001
Grup I 1239
(966-1387)
482,5
(399-756)
<0,001 -649
(-815 - -531)
Group II 1194,5
(1038,5-
1287,5)
982,5
(903,5-1154)
0,069 -106,5
(-189 - -88,5)
LAV (ml) <0,001
Grup I 90,5
(76-102)
72,7 (67-87) <0,001 -15,5
(-24 - -4,6)
Group II 84,1 86,8 0,327 2,1O
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Sfrom the beginning of the QRS complex to peak systolic velocity was measured as Ts
value for each segment. The difference between the shortest and the longest Ts value
was considered as the intraventricular delay time. Intraventricular dyssynchrony was
accepted if the intraventricular delay time >60 ms. Patient were randomized in to two
groups; as group 1 (n¼22) patients without intaventricular dyssynchrony and group 2
(n¼8) patients with intraventricular dyssynchrony. New York Heart Association
(NYHA) functional class, plasma BNP levels and echocardiographic measurements
were compared within and between groups before and after the levosimendan
infusion.
Results: Two groups were similar with respect to age, gender, heart failure etiology,
current medications, baseline LVEF and plasma BNP levels (Table 1). In both groups
statistically signiﬁcant improvement was observed in only mitral E/A after the
levosimendan infusion compared to baseline (p<0.025) (Table 2). In addition in
group 1 patients, all variables except for mitral A improved after the infusion
compared to baseline values (p<0.025) (Table 2). When group 1 and group 2 were
compared to each other, improvement in NYHA class, left ventricular EF, plasma
BNP levels, left atrial volume, left ventricular end-systolic volume and end-diastolic
volume were signiﬁcantly better in group 1 than group 2 after levosimendan
therapy (p<0.05) (Table 2).
Conclusion: Eventually, in our study we detected that both clinical and echocardio-
graphical improvement as well as the fall in plasma BNP level were statistically better
in the patients without intraventricular dyssynchrony after levosimendan infusion
(p<0,05). Intraventricular dyssynchrony may be used as an indicator in estimating
short-term response to levosimendan therapy.Table 1. Baseline characteristics of the study groups.
Group I (n¼22) Group II (n¼8) p
Age (year) 62,210,8 63,98,7 0,701
Gender (female/
male)
5/17 0/8 0,287
BSA (m2) 1,790,18 1,820,11 0,703
BMI (kg/m2) 26,64,6 24,73,8 0,305
Ischemic / dilated
cardiomyopathy
18/4 6/2 0,645
Smoker 11 (%50,0) 4 (%50,0) 1,000
Diabetes Mellitus 13 (%59,1) 3 (%37,5) 0,417
NYHA class 3 (3-4) 4 (3-4) 0,504
Heart rate (bpm) 83,413,3 85,422,0 0,822
SBP (mmHg) 115,314,5 117,710,7 0,664
DBP (mmHg) 68,79,8 71,28,1 0,514
LVEF (%) 25,45,9 21,76,1 0,139
BNP (pg/ml) 1239
(966-1387)
1194,5
(1038,5-1287,5)
0,629
QRS duration (ms) 110 (100-135) 127,5 (107,5-140) 0,534
ACE-I 15 (%68,2) 6 (%75,0) 1,000
ARB 4 (%18,2) - 0,550
Beta-blocker 13 (%59,1) 5 (%62,5) 1,000
Spironolactone 10 (%45,5) 4 (%50,0) 1,000
Digoxin 11 (%50,0) 5 (%62,5) 0,689
Anticoagulants 4 (%18,2) - 0,550
Antiaggregants 17 (%77,3) 8 (%100,0) 0,287
BSA: Body surface area, BMI: Body mass index, NYHA: New York Heart Association, SBP:
Systolic blood pressure, DBP: Diastolic blood pressure, LVEF: Left ventricular ejection fraction,
BNP: Brain natriuretic peptide, ACE-I: Angiotensin-converting enzyme inhibitor, ARB: Angio-
tensin receptor blocker
(65,5-111,5) (66-116,5) (-3,4 - 15)
LVEDV
(ml)
0,007
Grup I 214,450,63 203,248,29 <0,001 -11,214,34
Group II 213,952,65 221,656,71 0,287 7,718,97
LVESV (ml) <0,001
Grup I 163
(128-183)
137,5
(109-154)
<0,001 -18,5
(-30 - -8)
Group II 156 (128,5-
191,5)
158,5
(132,5-222)
0,249 7 (0 – 15,5)
LVEF (%) 0,003
Grup I 25,45,88 30,36,34 <0,001 4,94,16
Group II 21,76,14 20,96,34 0,339 -0,81,75
E (m/sn) 0,627
Grup I 0,950,25 0,780,28 0,008 -0,170,28
Group II 0,800,23 0,680,32 0,131 -0,120,20
A (m/sn) 0,354
Grup I 0,570,15 0,650,19 0,043 0,080,17
Group II 0,670,36 0,680,27 0,796 0,010,14
E/A 0,837
Grup I 1,740,52 1,330,63 0,013 -0,410,72
Group II 1,691,06 1,321,02 0,004 -0,370,25
NYHA: New York Heart Association, BNP: Brain natriuretic peptide, LAV: Left atrial volume,
LVEDV: Left ventricular end-diastolic volume, LVESV: Left ventricular end-systolic volume,
LVEF: Left ventricular ejection fraction pa In-group comparisons (p<0.025 is accepted as
statistically signiﬁcant according to Bonferroni adjustment) pb Inter-group comparisons
(p<0.05 is accepted as statistically signiﬁcant)
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Aim: Cardiovascular diseases are the leading cause of death in patients with chronic
kidney disease (CKD). Aspirin resistance (AR) worsens prognosis in cardiovascular
disease. The aim of this study was to detect AR prevalence in this patient group.
Methods: The 203 patients (mean age 61.8411.51and 128 (63.1%) were male) with
stable coronary artery disease included in the study were grouped into four study
groups according to their estimated glomerular ﬁltration rate (eGFR) values. Multi-
plate test was used to determine AR. Platelet aggregation results were presented as
aggregation unit (AU)*min and values over 300 AU*min were accepted as AR.
Results: 61 patients (30.04%) in the whole study population were found to have AR.
Differences were detected between AR ratios and multiplate values of the patient
groups (p¼0,006 and p¼0.002). AR ratio was highest in patient group 4 (eGFR valuesol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORALS
below 29 ml/min per 1.73 m2 and/or on chronic hemodialysis (HD) therapy whereas
there was little difference among other 3 groups. In multivariate analysis, while AR
status was independently related with female sex (Odds ratio [OR]¼2.31, Conﬁdence
interval [CI] 1,14-4.65, p¼0.019) and mean platelet volume (MPV) (OR¼1.68, CI
1,21-2.33, p¼0.002), multiplate test results were independently related with MPV
(b¼0.265, p<0.0001) and GFR (b¼-0.165, p¼0.025).
Conclusion: The AR ratio was found to be high in severe CKD patients, especially
HD patients, but not in mild and moderate CKD patients. This increased AR ratio in
severe CKD patients may affect the prognosis in these patients who already have an
increased risk for cardiovascular complications.Demographic Characteristics and Laboratory Values of the Study Groups
Group I
(n¼33)
Group II (n¼
47)
Group III
(n¼ 67)
Group IV
(n¼ 56) p value
Age, years 53.42 
10.32
62.02 
10.41
68.90 
7.86
58.69 
12.38
0.002
Male, n (%) 20 (60.6) 31 (66.0) 43 (64.2) 34 (60.7) 0.935
Smoking, n (%) 13 (39.4) 19 (40.4) 25 (37.3) 9 (16.1) 0.022
Hypertension, n (%) 20 (60.6) 35 (74.5) 59 (88.1) 40 (71.4) 0.016
Diabetes mellitus, n (%) 11 (33.3) 13 (27.7) 30 (44.8) 20 (35.7) 0.293
Hypercholesterolemia,
n (%)
22 (66.7) 32 (68.1) 49 (73.1) 35 (62.5) 0.656
Body mass index,
kg/m2
29.13 
4.39
29.02 
5.73
28.01 
4.20
29.42 
3.22
0.765
Medication
b-blockers, n (%) 21 (63.6) 36 (76.6) 56 (83.6) 27 (48.2) <0.0001
RAS blockers, n (%) 18 (54.5) 31 (66.0) 54 (80.6) 20 (35.7) <0.0001
Calcium antagonists,
n (%)
4 (12.1) 7 (14.9) 15 (22.4) 13 (23.2) 0.449
Statins, n (%) 19 (57.6) 23 (48.9) 38 (56.7) 8 (14.3) <0.0001
Diuretics, n (%) 6 (18.2) 20 (42.6) 26 (38.8) 20 (35.7) 0.129
Laboratory values
Creatinine, mg/dL 0.71  0.13 0.97  0.16 1.48  0.27 7.52  2.79 <0.0001
BUN, mg/dL 12.60 
3.33
19.57 
8.14
29.74 
12.55
67.66 
13.37
<0.0001
WBC,  103/ml 8.02  2.43 7.31  1.38 7.75  1.92 7.74  2.62 0.513
MPV, fL 8.73  0.75 8.60  0.81 8.19  0.92 9.73  1.37 <0.0001
Hemoglobin, g/dL 13.87 
1.42
12.99 
1.72
12.13 
1.77
11.22 
1.61
<0.0001
Platelet count, 
103/ml
269.06 
82.33
234.61 
60.84
238.72 
55.17
190.49 
69.67
<0.0001
AR
Multiplate, AU*min 229.36 
191.13
220.38 
151.39
243.64 
189.03
351.39 
228.39
0.002
AR, n (%) 7 (21.2) 12 (25.5) 15 (22.4) 27 (48.2) 0.006
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Inverted T-Stenting and Small Protrusion (TAP Stenting) Technique for
Coronary Bifurcation Lesions: A New Technique
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1Yildirim Beyazit University, Faculty of Medicine, Division of Cardiology, Ankara,
2Ataturk Education and Research Hospital, Division of Cardiology, Ankara
Introduction: T-stenting and small protrusion (TAP stenting), which is a novel
modiﬁcation of the T stenting technique has been recently described and reported to be
associated with good clinical outcomes. Although “inverted TAP (T-Stenting and
Small Protrusion) stenting technique” is one of the theoretically possible inverted
techniques in the classiﬁcation of bifurcation lesions tretment techniques, there is no
published data available on the use of this technique for treatment of bifurcation
lesions. We have performed “inverted TAP stenting technique” in 7 patients who have
bifurcation lesions with a high bifurcation angle and without mismatch between the
diameters of proximal MV and SB. With this technique, we fully covered the side
branch ostium without multi-stent struts layers. To the best of our knowledge this is
the ﬁrst report of “inverted TAP stenting technique” in bifurcation lesions and
demonstrated the feasibility of this technique. Here, we report our experience with this
technique.
Methods: Both the MV and SB were wired. Predilatation of the SB were performed in
all patients. If needed, predilatation was also performed for the MV with an undersized
balloon. We implanted the ﬁrst stent from the proximal MV through the SB (Figure 1).
The wire in the distal MV was jailed. The proximal part of the stent was postdilated
(proximal optimisation technique) to optimise stent apposition in the proximal MV
and to facilitate distal MV access (Figure 2). After recrossing the distal MV and
dilation of stent struts (Figure 3), we placed the second stent into the distal MV
with minimal protrusion into the ﬁrst stent with an uninﬂated balloon in the SB as
in TAP stenting technique (Figure 4). After implantation of the stent, the balloon of
the stent was slightly pulled back and ﬁnal kissing balloon was performed by
inﬂating simultaneously the stent balloon and SB balloon (Figure 5).
Conclusion: We performed this technique for bifurcation lesions with high angle and
large SB in diameter with large territory of distribution. There was no mismatch
between the size of the proximal MV and SB. Our aim was to fully cover the SB
ostium and avoid multi-stent layering. Like in culotte stenting, we implanted the ﬁrst
stent from the proximal MV through SB with wide angle.But the second stent was
implanted to distal MV with minimal protrusion within the ﬁrst stent. The access to
the distal MV was easy because the recrossing was in the direction of the MV.
Procedure was successful in all 7 patients. In conclusion, inverted TAP stenting
technique may be used in patients who have bifurcation lesions with high angle and
without mismatch between the diameters of proximal MV and SB. Thus we can fully
cover the SB ostium without multi-stent struts layers.LS C61
